ATP13A4 and melanoma: Of note, ATP13A4 underwent amplification in over 10% of patients with ovarian cancer, cervical cancer, head and neck cancer, endometrial cancer, uterine endometrioid carcinoma, bladder cancer, melanoma, lung cancer and breast cancer.